Evidence-Based Summary
MOTS-c and AOD-9604 are both investigated for metabolic health and body composition, but they operate through completely different biological levels. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is an endogenous 16-amino-acid peptide encoded within the mitochondrial genome, discovered in 2015 by Changhan Lee and David Cohen at USC. MOTS-c functions as a mitochondrial retrograde signaling molecule: in response to metabolic stress, it translocates to the nucleus and activates AMP-activated protein kinase (AMPK) and the AICAR pathway, inhibiting the folate-methionine cycle and dramatically improving skeletal muscle glucose disposal, metabolic flexibility, and physical endurance in rodent models. In contrast, AOD-9604 is a synthetic 16-amino-acid peptide replicating the C-terminal lipolytic domain of human growth hormone (hGH 177-191). Developed in the late 1990s, AOD-9604 was hypothesized to trigger direct fat breakdown in adipocytes via beta-3 adrenergic pathways while avoiding the diabetogenic and IGF-1 elevating actions of intact GH. However, in a 536-patient Phase 2b human randomized trial, AOD-9604 failed to produce statistically significant weight loss over placebo and was abandoned by its pharmaceutical sponsor. Neither peptide is approved by the FDA or EMA, the FDA has placed AOD-9604 under compounding restrictions, and both are prohibited in competitive sports at all times by WADA: AOD-9604 is named under S2.2.3 (growth hormone fragments) and MOTS-c under S4.4.1 (metabolic modulators).
Quick Comparison: MOTS-c vs AOD-9604
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | MOTS-c | AOD-9604 |
|---|---|---|
| Biological origin | Endogenous mitochondrial genome (12S rRNA sORF) | Synthetic C-terminal fragment of human growth hormone |
| Peptide length & structure | 16 amino acids: MRWQEMGYIFYPRKLR (2174.6 Da) | 16 amino acids: Tyr-hGH[177-191] cyclic (1815.1 Da) |
| Primary molecular target | AMPK activation, folate-methionine cycle inhibition | Adipocyte lipolytic pathways (Putative beta-3 AR) |
| Target tissue | Skeletal muscle, liver, systemic cellular metabolism | Subcutaneous and visceral white adipocytes |
| Impact on insulin sensitivity | Improves skeletal muscle glucose disposal & GLUT4 | Neutral (Engineered specifically to avoid insulin antagonism) |
| Human Phase 2b trial result | Phase 1 early clinical trials in metabolic disease | Failed 536-patient Phase 2b RCT for weight loss |
| FDA regulatory status | Unapproved investigational biomolecule | Unapproved; formerly FDA Category 2, now “nominated but withdrawn” |
| WADA anti-doping status | Prohibited at all times (Section S2: Metabolic modulators) | Prohibited at all times (Section S2: Peptide fragments) |
Mitochondrial Retrograde Signaling vs Isolated Fragment Lipolysis
Contrasting whole-cell energy sensor activation with localized adipocyte receptor hypotheses.
MOTS-c: AMPK Activation & Folate Cycle Modulation
Primary Target: Intracellular nuclear translocation; AMPK pathway
Affinity Profile: Endogenous physiological signaling peptide
MOTS-c is transcribed from mitochondrial 12S rRNA and exported to the cytoplasm. Under metabolic stress or exercise, it enters the cell nucleus to bind chromatin and regulate adaptive nuclear gene expression. In the cytoplasm, it inhibits the folate-methionine cycle, increasing 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP/AICAR) levels, which directly allosterically activates AMPK, stimulating glucose uptake into skeletal muscle via GLUT4 and increasing fatty acid oxidation.
AOD-9604: Putative Adipocyte Beta-3 Adrenergic Cross-Talk
Primary Targets: Does not bind intact growth hormone receptor (GHR)
Affinity Profile: Lacks the N-terminal functional GHR binding domain
AOD-9604 isolates residues 177-191 of hGH stabilized by an internal disulfide bond. In rodent fat cells, it was reported to upregulate beta-3 adrenergic receptor activity, stimulating hormone-sensitive lipase (HSL) and releasing free fatty acids. However, human white adipocytes express markedly lower beta-3 AR densities than rodents, explaining why this mechanism failed to produce clinically meaningful weight reduction in human clinical trials.
Investigational Status & FDA Compounding Prohibitions
The regulatory realities facing both experimental peptides.
MOTS-c Status & Formulations
Not approved by the FDA or EMA for human clinical use.
AOD-9604 Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Critical Regulatory Distinction
Neither peptide is approved by the FDA or EMA. FDA previously placed AOD-9604 in Category 2 of its interim compounding policy; FDA now lists both AOD-9604 and MOTS-c as “nominated but withdrawn”, which is not a safety clearance.
Early Human Research vs Completed Phase 2b Trial
Evaluating the human evidence base for both metabolic peptides.
MOTS-c: MOTS-c Clinical Research
In preclinical studies (Lee et al., Cell Metab 2015; Nat Commun 2021), MOTS-c prevented high-fat diet-induced insulin resistance in mice and dramatically enhanced physical capacity in aging animals. Early human pharmacokinetic and Phase 1 safety studies have been conducted by CohBar (CB4211), but Phase 2 efficacy data are pending.
AOD-9604: AOD-9604 Human Clinical Trial
In a 24-week Phase 2b randomized, double-blind, placebo-controlled trial in 536 obese adults (Metabolic Pharmaceuticals 2007), four different daily doses of AOD-9604 failed to demonstrate statistically significant weight loss compared to placebo, terminating commercial development for obesity.
Tolerability & Research Uncertainties
Both substances lack long-term human safety surveillance.
| Safety Consideration | MOTS-c | AOD-9604 |
|---|---|---|
| Carbohydrate metabolism | Improves glucose tolerance in preclinical models | Does not alter blood glucose or insulin sensitivity |
| IGF-1 stimulation | Does not stimulate systemic IGF-1 | Does not elevate systemic IGF-1 |
| Anti-doping sanction risk | Prohibited (WADA Category S2) | Prohibited (WADA Category S2) |
What MOTS-c and AOD-9604 Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
16-Amino-Acid Length
Both peptides are exactly 16 amino acids long, evaluated for fat loss and metabolic regulation.
WADA Prohibition
Both substances are banned at all times in competitive athletics under WADA Section S2.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Genomic Origin
MOTS-c is an endogenous peptide encoded in the mitochondrial genome; AOD-9604 is a synthetic fragment of pituitary hGH.
Primary Action
MOTS-c acts as an intracellular energy sensor activating AMPK; AOD-9604 acts as a putative adipocyte lipolytic fragment.
Clinical Trial Status
AOD-9604 failed in a 536-patient Phase 2b trial; MOTS-c remains in active early-stage investigational development.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
AOD-9604 and MOTS-c melt fat effortlessly without diet or exercise
insufficientUnverified vendor marketing contradicting published clinical trial evidence.
AOD-9604 failed to beat placebo in a large Phase 2b trial. MOTS-c acts as an exercise mimetic in animals, but human efficacy and safety are unproven in published Phase 3 trials.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Preclinical Metabolic & AMPK Modulation
MOTS-c consistently activates AMPK and improves glucose tolerance in animal models.
Human Clinical Weight Loss
Neither peptide is proven in human Phase 3 RCTs; AOD-9604 failed in Phase 2b.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Human MOTS-c Exercise Dynamics
Characterizing whether endogenous MOTS-c levels change dynamically in response to acute high-intensity resistance versus aerobic exercise in human skeletal muscle.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Peer-Reviewed Article
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces diet-induced obesity
-
Clinical Trial Report
Phase 2B clinical trial of AOD9604 in obesity